Tumor electric field therapy is available for the first time in China! What is tumor electric field therapy?

Malignant tumor electrostatic field treatment is a kind of treatment method executed according to the portable and minimally invasive medical equipment, and its mechanism is based on the low compressive strength, high-frequency (200kHz) communicating exchange electrostatic field, efficacy in the propagation of microtubule proteins of the tumor cells, affecting the mitotic division of the malignant tumor cells, and causing the affected tumor cells to apoptosis and inhibiting the growth of the tumor.

Glioma refers to the tumor originating from the glial cells of the brain, and is the most common primary intracranial tumor. The World Health Organization (WHO) classification of central nervous system tumors divides gliomas into grades I-IV, with grades I and II being low-grade gliomas and grades III and IV being high-grade gliomas. Glioblastoma (GBM) is the highest grade as well as the most malignant (grade IV) glioma, accounting for 45% of primary intracranial malignant tumors.

As the most common malignant tumors of the nervous system, gliomas are highly malignant, fast-growing, short-lived, prone to postoperative recurrence, and highly disabling, and are considered to be one of the most problematic and refractory tumors in neurosurgical treatment.

Tumor electric field therapy is a kind of tumor treatment that uses a specific electric field frequency to interfere with cell division, inhibit tumor growth, and cause cancer cells affected by the electric field to die. Its most common adverse effect is mild to moderate skin irritation. Tumor electric field therapy has been approved in certain countries and regions for the treatment of adult patients with glioblastoma and mesothelioma, two of the most difficult types of cancer to treat.

The world's first and only U.S. FDA-approved product for tumor electric field therapy has treated more than 15,000 glioblastoma patients worldwide. Tumor electric field therapy has also received FDA approval for the treatment of malignant pleural mesothelioma (MPM) through the Humanitarian Device Exemption (HDE) pathway, with a marketing application for this indication to be subsequently submitted in China.

In addition to glioblastoma and MPM, multiple global Phase 3 pivotal clinical studies are underway to evaluate the efficacy of oncolytic electric field therapy for the treatment of brain metastases, non-small cell lung cancer, pancreatic cancer, and ovarian cancer, as well as Phase 2 clinical studies in hepatocellular carcinoma and gastric cancer.